lyrica pregabalin capsule lyrica pregabalin solution
1 INDICATIONS AND USAGE LYRICA is indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: • neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ) • Postherpetic neuralgia (PHN) ( 1 ) • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older ( 1 ) • fibromyalgia ( 1 ) • neuropathic pain associated with spinal cord injury ( 1 )
parke-davis div of pfizer inc
CAPSULE WHITE PGN 25
Related Pills
lyrica pregabalin capsule lyrica pregabalin solution
parke-davis div of pfizer inc
lyrica pregabalin capsule lyrica pregabalin solution
parke-davis div of pfizer inc
lyrica pregabalin capsule lyrica pregabalin solution
parke-davis div of pfizer inc
Lyrica pregabalin 100 MG Oral Capsule Lyrica
Parke-Davis Div of Pfizer Inc
Lyrica pregabalin 50 MG Oral Capsule Lyrica
Parke-Davis Div of Pfizer Inc
Lyrica 300 MG Oral Capsule
Parke-Davis Div of Pfizer Inc
Lyrica 150 MG Oral Capsule
Parke-Davis Div of Pfizer Inc
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING 25 mg capsules: white, hard-gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 25" on the body; available in: Bottles of 90: NDC 0071-1012-68 50 mg capsules: white, hard-gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 50" and an ink band on the body, available in: Bottles of 90: NDC 0071-1013-68 Unit-Dose Blister Packages of 100: NDC 0071-1013-41 75 mg capsules: white/orange hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 75" on the body; available in: Bottles of 90: NDC 0071-1014-68 Unit-Dose Blister Packages of 100: NDC 0071-1014-41 100 mg capsules: orange, hard-gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 100" on the body, available in: Bottles of 90: NDC 0071-1015-68 Unit-Dose Blister Packages of 100: NDC 0071-1015-41 150 mg capsules: white hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 150" on the body, available in: Bottles of 90: NDC 0071-1016-68 Unit-Dose Blister Packages of 100: NDC 0071-1016-41 200 mg capsules: Light orange hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 200" on the body, available in: Bottles of 90: NDC 0071-1017-68 225 mg capsules: white/light orange hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 225" on the body; available in: Bottles of 90: NDC 0071-1019-68 300 mg capsules: white/orange hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 300" on the body, available in: Bottles of 90: NDC 0071-1018-68 20 mg/mL oral solution: 16 fluid ounce white high density polyethylene (HDPE) bottle with a polyethylene-lined closure: 16 fluid ounce bottle NDC 0071-1020-01 Storage and Handling Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).
More pills like CAPSULE PGN 25